Summit Corp rises on technology agreement
Shares in Summit Corporation, an Oxford based drug developer, soared 20 per cent on Tuesday after it announced it has entered a technology licence agreement with Bristol-Myers Squibb Company. Under the agreement, Bristol-Myers will use Summit's Seglin technology to identify and develop drug candida
Read more